BioRegenx, Inc. Overview

Company Structure

• Founded: December 23, 1998, in Nevada.
• Former Name: Findit, Inc.; renamed to BioRegenx, Inc. effective March 8, 2024.
• Ownership Transition: The merger resulted in 90% of voting securities being exchanged for shares, with significant stock retirements to improve capital structure.
• Employees: The company currently employs 5 full-time employees and 5 independent contractors.

Subsidiaries and Key Offerings

1. DocSun BioMedical Holdings, Inc.

   • Acquisition Date: January 11, 2024.
   • Common Shares: BioRegenx exchanged 76,800,000 shares for all outstanding DocSun securities.
   • Technology:
     • DocSun AI Engine integrates three technologies: ballistocardiography, photoplethysmography, and optical coherence tomography for non-invasive health monitoring.
   • Major Contracts:
     • Technical services in China with a projected total revenue share of 40% from product licensing.
     • A License Agreement with NuLife Sciences for a world-wide non-exclusive license costing $3.50 per subscriber.
   • Revenue Generation: Planned revenues from licensing and distribution agreements.

2. Microvascular Health Solutions, LLC (MVHS)

   • Products:
     • Endocalyx Pro™: A dietary supplement aimed at enhancing microvascular health.
     • GlycoCheck™: Software and medical device for capillary health monitoring.
   • Research and Compliance: Engaged in multiple global studies and complies with GMP regulations.
   • Revenue Sources:
     • Sales from GlycoCheck systems priced between $14,900 to $32,000.
     • Recurring revenue from subscription services based on scans performed.

3. NuLife Sciences, Inc.

   • Function: Marketing and distribution of health-related products including MyBodyRx supplements and hydrogen water products.
   • Collaborations: Developing health and wellness apps integrated with telehealth solutions.
   • Projected Release: TruScan.Ai mobile app expected in Q3 2025, merging gene-based solutions with health metrics.

4. Findit Ai Connect, Inc.

   • Founded: Simultaneously with the merger on March 8, 2024.
   • Websites: Owns Findit.com and Classworx.com, offering social media tools and a content platform.

Financial Aspects

• Revenue Composition:
  • Approximately 88% of total revenue from U.S. customers as of the latest reporting period.
• Focus: Exploring international market expansion and diversifying revenue streams.

Market Position and Strategy

Market Size

• Healthcare Market: Valued at $8.96 trillion in 2024 with projected growth.
• Telehealth Market: Estimated at $161.64 billion in 2024, growing to $791.04 billion by 2032.

Growth Potential

• Focus on remote health monitoring and telehealth as emerging trends.
• Development of AI-driven solutions in health monitoring and preventative healthcare.

Competitive Landscape

• Faces competition from established firms and emerging startups within the health, wellness, and telehealth sectors.

Marketing Strategy

• Engages in both business-to-business (B2B) and business-to-consumer (B2C) strategies focusing on:
  • Professional engagement via training and industry events.
  • Collaborating on research and clinical trials.
  • Enhancing direct sales channels for consumers.

Summary

BioRegenx, Inc. operates at the intersection of healthcare and technology, emphasizing innovative health monitoring solutions through its subsidiaries. The company is focused on leveraging advanced technology for healthcare improvements while maintaining a nimble operational model with a small team and extensive digital presence. With ongoing projects aimed at broadening its product offerings and a solid foundation in the telehealth market, it is positioned for growth amidst an evolving healthcare landscape.